Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

GM-CSF autoantibodies: a novel diagnostic marker and personalized therapeutic for Crohn's disease

FY 2020-21

Summary
Crohn's disease (CD) is a severe and chronic inflammatory disorder of the gastrointestinal tract. Affecting almost 400 per 100,000 Canadians, CD currently has no cure. Research suggests that CD results from a combination of genetic, environmental, and lifestyle factors, leading to dysregulated immune activation in the gut. Mononuclear phagocytes (MNPs) are crucial cells that balance intestinal immune activity and are dependent on granulocyte-macrophage colony stimulating factor (GM-CSF), a key protein that supports growth and function of MNPs. Interestingly, our study of two retrospective cohorts of CD patients revealed that a large proportion of patients display increased levels of autoantibodies in their blood that specifically bind to GM-CSF up to 7 years prior to disease diagnosis. Characterization of these antibodies demonstrated that they specifically neutralize the function of GM-CSF through binding sugar chains on the protein, dampening MNP activity. In line with our results, mutations in genes involved in GM-CSF signaling have been identified as strong risk factors for CD, emphasizing the importance of GM-CSF in intestinal health. In this proposal, we aim to genetically engineer GM-CSF variants that can escape neutralization by autoantibodies in CD patients. These variants will be used to develop a diagnostic assay to identify CD patients and classify them based on their reactivity against GM-CSF. Collectively, this proposal opens an avenue towards a predictive diagnostic and personalized treatment strategy for CD.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449769
Name
Tai Siu Ling
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
GM-CSF autoantibodies: a novel diagnostic marker and personalized therapeutic for Crohn's disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoantibody; Barrier Integrity; Crohn'S Disease; Cytokine; Diagnostic; Genetic Engineering; Intestinal Immune Balance; Macrophages; Personalized Treatment
Abstract
Crohn's disease (CD) is a severe and chronic inflammatory disorder of the gastrointestinal tract. Affecting almost 400 per 100,000 Canadians, CD currently has no cure. Research suggests that CD results from a combination of genetic, environmental, and lifestyle factors, leading to dysregulated immune activation in the gut. Mononuclear phagocytes (MNPs) are crucial cells that balance intestinal immune activity and are dependent on granulocyte-macrophage colony stimulating factor (GM-CSF), a key protein that supports growth and function of MNPs. Interestingly, our study of two retrospective cohorts of CD patients revealed that a large proportion of patients display increased levels of autoantibodies in their blood that specifically bind to GM-CSF up to 7 years prior to disease diagnosis. Characterization of these antibodies demonstrated that they specifically neutralize the function of GM-CSF through binding sugar chains on the protein, dampening MNP activity. In line with our results, mutations in genes involved in GM-CSF signaling have been identified as strong risk factors for CD, emphasizing the importance of GM-CSF in intestinal health. In this proposal, we aim to genetically engineer GM-CSF variants that can escape neutralization by autoantibodies in CD patients. These variants will be used to develop a diagnostic assay to identify CD patients and classify them based on their reactivity against GM-CSF. Collectively, this proposal opens an avenue towards a predictive diagnostic and personalized treatment strategy for CD.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tai, Siu Ling
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~